Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.42 |
| ▸ | RORB | Q92753 | 6/20 | 0.39 |
| ▸ | RORC | P51449 | 4/20 | 0.39 |
| ▸ | PTAFR | P25105 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2478195 | 0.82 | RORC (0.50) | ADORA1ADORA2ARORBRORCMAOB | |
| SCHEMBL4080804 | 0.79 | ADORA1 (0.43) | ADORA1ADORA2ARORBRORCMAOB | |
| SCHEMBL4090647 | 0.79 | ADORA1 (0.46) | ADORA1ADORA2ARORBRORCPTAFR | |
| SCHEMBL4091364 | 0.79 | ADORA1 (0.56) | ADORA1ADORA2ARORBRORCPTAFR | |
| SCHEMBL8881894 | 0.78 | RORB (0.44) | ADORA1ADORA2ARORBRORCMAOB | |
| SCHEMBL5735874 | 0.75 | RORC (0.47) | RORBRORCMAOBCNR2 | |
| SCHEMBL4078130 | 0.75 | ADORA1 (0.40) | ADORA1ADORA2ARORBRORCMAOB | |
| SCHEMBL30679626 | 0.74 | RORC (0.45) | ADORA1ADORA2ARORBRORCMAOB | |
| SCHEMBL4076829 | 0.73 | RORB (0.41) | ADORA1RORBRORCMAOBALDH1A1 | |
| SCHEMBL30861657 | 0.72 | RORB (0.50) | ADORA1ADORA2ARORBRORCMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013049725-A2 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2013-04-04 | — | — | WO | claimed |
| US-20140241990-A1 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013049725-A2 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2009049362-A1 | A1 ADENOSINE RECEPTOR ALLOSTERIC ENHANCERS | MONASH UNIVERSITY (AU) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140241990-A1 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885ADORA2A 1/4885RORB 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.